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Brain DZ dopamine receptors have been solubilised using lysophosphatidylcholine. The inclusion of 
proteinase inhibitors during solubilisation enables a preparation to be obtained containing a high 
proportion of solubilised Dz receptors with pharmacological properties similar to those of membrane- 
bound D2 receptors. 
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1. INTRODUCTION 2. EXPERIMENTAL 
Brain dopamine receptors have been studied in- 
tensively over the past few years in their native 
membrane-bound state (e.g., [l]). We have studied 
in detail one class of dopamine receptor in bovine 
brain using [3H]spiperone binding [2,3] and the 
pharmacological characteristics are those of a DZ 
receptor. A complete understanding of the mechan- 
ism of action of this receptor will be obtained only 
when the receptor is isolated and fully character- 
ised. A prerequisite for this is solubilisation of 
active receptors from the membrane using deter- 
gents; reports have appeared describing the use of 
CHAPS (3- [(3-cholamidopropyl)dimethylammo- 
nio]-l-propane sulphonate [4]) and digitonin [5,6] 
for solubilisation of active brain Dz receptors. We 
have screened a series of ionic, non-ionic and zwit- 
terionic detergents for solubilisation of brain DZ 
receptors ([7], J.M. Hall, M.W., P.G.S., unpub- 
lished) and have found that lysophosphatidylcho- 
line (LPC) is a useful detergent for this purpose. 
Here, we describe some of the characteristics of the 
LPC-solubilised receptors. 
Benzamidine, benzethonium chloride, EGTA, 
iodoacetic acid, leupeptin, LPC, pepstatin A and 
phenylmethanesulphonylfluoride w re from Sigma 
(London) (Poole); EDTA from Fisons Ltd 
(Loughborough, Leicestershire); methylmethane- 
thiolsulphonate from Aldrich Chemical Company 
(Gillingham, Dorset); all other chemicals were ob- 
tained from suppliers given in [2,3]. 
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A mixed mitochondrial-microsomal prepara- 
tion was made from bovine caudate nucleus as in 
[3] and Dz receptors were solubilised from this 
preparation as in [7]. Mitochondrial-microsomal 
preparation (-2 mg protein/ml) and LPC at the 
concentration shown (generally 0.1%) in a buffer 
containing sucrose (0.32 M), Hepes [4-(2-hydroxy- 
ethyl)-piperazine-ethanesulphonate] (20 mM), 
EDTA (0.1 mM), dithiothreitol (0.1 mM) at pH 
7.4 were mixed by homogenisation (Teflon/glass) 
and the solubilised preparation (-1 mg pro- 
tein/ml) was obtained after centrifugation (100000 
x g, 60 min). In some experiments proteinase in- 
hibitors were included (EDTA (1 mM), EGTA 
(I mM), phenylmethane sulphonylfluoride 
(0.1 mM), benzethonium chloride (0.1 mM) 
pepstatin A (18 PM)). 
Solubilised receptors were assayed by incubating 
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0.45 ml of the solubilised preparation with 
[3H]spiperone (-1 nM for displacement ex- 
periments) and pargyline (10 PM) in 0.5 ml final 
vol. buffer containing proteinase inhibitors and 
other drugs where indicated at 4°C for the time 
shown (in most experiments this was 4 h although 
some were run for 16 h). The incubation was ter- 
minated by the addition of 0.1 ml of a suspension 
of charcoal (Norit GSX, 10%) pre-equilibrated at 
4°C with bovine serum albumin (2.2%) in buffer 
which was mixed and centrifuged (12000 x g, 
2.5 min). Aliquots (0.3 ml) of the supernatant 
were taken for determination of bound radioactivi- 
ty as in [2,3]. Specific binding of [3H]spiperone 
was defined as the difference between parallel 
assays containing 1 PM (- )- and (+ )-butaclamol. 
I&-Values are the concentrations of substances 
required to displace 50% of the specifically bound 
[3H]spiperone. Protein concentrations were deter- 
mined as in [2,3] except hat 3.2% SDS was includ- 
ed as in [7]. 
3. RESULTS 
Increasing concentrations of LPC gave increas- 
ing solubilisation of protein and [3H]spiperone bin- 
ding sites from bovine caudate nucleus membranes 
(fig.1). LPC at 0.1% was used for subsequent ex- 
periments as this gave a high degree of solubilisa- 
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Fig. 1. Solubilisation of specific [3H]spiperone binding 
and protein from bovine caudate nucleus by LPC. 
Supplementary proteinase inhibitors were absent. 
tion. Under these conditions roughly 10% of 
[3H]spiperone binding sites are extracted assuming 
that the solubilised binding is to DZ receptors (see 
below). The time course of [3H]spiperone binding 
to the solubilised preparation is shown in fig.2 and 
in studies reported below an incubation time of 4 h 
was generally used. [3H]Spiperone specifically 
bound to the solubilised preparation was defined 
as the difference in binding in parallel assays con- 
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Fig.2. Time-course for specific binding of [3H]spiperone 
to LPC-solubilised preparation of bovine caudate 
nucleus. Proteinase inhibitors were present as in fig.4. 
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Fig.3. Displacement of [3H]spiperone (1 nM) binding 
from an LPC-solubilised preparation of bovine caudate 
nucleus by various competing substances. Supple- 
mentary proteinase inhibitors were absent. 
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taining 1 ,uM ( - )- and ( + )-butaclamol, respective- 
ly and the precise characteristics of the solubilised 
preparation were determined in displacement ex- 
periments (fig.3). 
Non-radioactive spiperone displaced 84% of the 
[3H]spiperone binding indicating that true non- 
specific binding was 16% of the total. However, 
the drug butaclamol, which exists in (+)- and (-) 
stereoisomeric forms, offers a more discriminating 
test of the character of the binding. At membrane- 
bound Dz receptors (+)-butaclamol is roughly 
800-times more potent than ( - )-butaclamol in 
displacing [3H]spiperone binding [2]. In the LPC- 
solubilised preparation the potency ratio (ZCSO 
( - )-butaclamol/ZCso (+ )-butaclamol) is only 12. 
This could be because upon solubilisation the Dz 
receptors partly lose their ability to discriminate 
between the isomers of butaclamol or that 
[3H]spiperone binding in the LPC-solubilised 
preparation is to D2 receptors (with a high ability 
to discriminate between the isomers of butaclamol) 
and to a class of sites with little or no ability to dis- 
criminate between the isomers of butaclamol 
(non-stereospecific sites). Examination of the dis- 
placement curves reveals a portion of the binding 
(-30%) where ( + )-butaclamol (lo-300 nM) 
displaces [3H]spiperone binding but ( - )- 
butaclamol does not. The selective Dz receptor 
antagonist sulpiride also displaces -30% of the 
binding, whereas the specific serotonergic an- 
tagonist mianserin shows no high affinity displace- 
ment indicating the absence of serotonergic sites. 
This latter finding is important as the bovine 
caudate nucleus membranes used for solubilisation 
contain comparable numbers of dopaminergic and 
serotonergic sites [2]. Assuming this analysis, the 
remaining binding is displaced with roughly equal 
affinities by the two isomers of butaclamol. Hence 
the total solubilised [3H]spiperone binding consists 
of 30% Dz receptors, 54% non-stereospecific sites 
(spirodecanone sites [6,8]) and 16% non-specific 
binding. This analysis also validates the use of 
1 ,uM (+)- and (-)-butaclamol for defining 
specific D2 receptor binding in the LPC-solubilised 
preparation. 
systems [9]. When inhibitors of the 4 main classes 
of proteinase [lo] (EDTA, EGTA, phenylmethane- 
sulphonylfluoride, benzethonium chloride, 
pepstatin A) were included during solubilisation 
the potency ratio for the isomers of butaclamol in- 
creased to 170 and the pharmacological profile 
changed considerably. The major contributor to 
this change was benzethonium chloride (see section 
4). 
In displacement experiments on this preparation 
(fig.4), non-radioactive spiperone gave a biphasic 
displacement curve, -60% of the bound 
[3H]spiperone being displaced with high affinity. 
Displacements by ( + )-butaclamol and the specific 
DZ receptor antagonist, domperidone were also 
biphasic whereas ( - )-butaclamol was virtually in- 
active at the concentrations used. Mianserin show- 
ed no high affinity displacement indicating the 
absence of a significant serotonergic omponent of 
binding. The high affinity components of binding 
of ( + )-butaclamol and domperidone indicate that 
the total [3H]spiperone binding consists of -40% 
D2 receptor binding, the remainder consisting of 
non-stereospecific sites and non-specific binding 
sites. A comparison of ZCso values for displacing 
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The proportion of specific binding observed in 
these experiments is rather low so we have investi- 
gated the effect of adding proteinase inhibitors 
during solubilisation as such inhibitors have been 
shown to influence receptor solubilisation in some 
Fig.4. Displacement of [3H]spiperone (1nM) binding 
from an LPC-solubilised preparation of bovine caudate 
nucleus (obtained in the presence of proteinase in- 
hibitors) by various competing substances. EDTA 
(1 mM), EGTA (1 mM), phenylmethanesulphonyl- 
fluoride (0.1 mM) and benzethonium chloride (0.1 mM) 
were present during solubilisation and assay of 
[3H]spiperone binding sites - pepstatin A was not 
included in these experiments as it was without effect 
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I-) - butaclamol 
(section 4). 
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Table 1 
Z&J values (nM) for displacement of specific 
[3H]spiperone binding to LPC-solubilised preparations 
of bovine caudate nucleus 
Displacing substance - Proteinase + Proteinase 
inhibitors inhibitors 
( + )-Butaclamol 129 56 
( - )-Butaclamol 1514 9550 
Domperidone 229 79 
( f )-Mianserin 355 2818 
Spiperone 15 2 
( f )-Suipiride 631 3400 
ZCse values (concentrations of substance giving 50% 
inhibition of specific [3H]spiperone (-1 nM) binding 
were determined as in section 2 to LPC-solubiIised pre- 
parations obtained in the presence or absence of 
proteinase inhibitors. Pepstatin A was not included 
(see fig.4) 
drugs in the preparations obtained with and 
without proteinase inhibitors is given in table 1. 
Saturation analysis of [3H]spiperone binding to the 
preparation obtained in the presence of proteinase 
inhibitors indicated a dissociation constant of 0.24 
+ 0.09 nM (mean & SD, 5 expts) (J.M. Hall, 
P.G.S., unpublished); there were slight indications 
of the binding of [3H]spiperone to additional ower 
affinity sites in some preparations. 
4. DISCUSSION 
These experiments validate the use of LPC as a 
useful detergent for solubilisation of active Dz 
receptors. In the preparation obtained using LPC 
alone [3H]spiperone binding is to D2 receptors but 
a large number of sites is also present which show 
low stereospecificity for binding the isomers of 
butaclamol (non-stereospecific or spirodecanone 
sites). If proteinase inhibitors are added during 
solubilisation specific [3H]spiperone binding to Dz 
receptors represents a larger proportion of the total 
[3H]spiperone binding and the yield of solubilised 
receptors is also slightly increased (by 18% over the 
control value). The major effect, however, is that 
the pharmacological profile is much clearer and the 
presence of Dz receptors with properties similar to 
those of membrane-bound receptors can easily be 
discerned (fig.3,4; table 1). The relative impor- 
100 
tance of the different proteinase inhibitors has 
been determined in separate experiments (not 
shown). Pepstatin A, an inhibitor of aspartic 
proteinases [lo] does not contribute to these 
changes whereas benzethonium chloride, reported 
to be an inhibitor of cysteine proteinases [1 1] and 
arylaminopeptidases [ 121 is essential for observing 
these effects. Serine proteinase and metalloprotein- 
ase inhibition are unimportant as EDTA, EGTA 
and phenylmethanesulphonylfluoride are 
themselves without effect. Other inhibitors of cys- 
teine proteinases (benzamidine, iodoacetate, 
leupeptin, methylmethanethiolsulphonate) were 
without effect so that the effects of benzethonium 
may be unrelated to proteinase inhibition or alter- 
natively inhibition of a specific benzethonium sen- 
sitive proteinase may be occurring. Benzethonium 
is also reported to be a detergent [13] and to in- 
teract with other detergents [14] so that the com- 
bination of LPC and benzethonium may solubilise 
a different combination of proteins or a different 
conformational state of the same proteins. Alter- 
natively, benzethonium may alter non-specific and 
non-stereospecific binding of [3H]spiperone. It is 
not possible at present to distinguish these alter- 
natives but in digitonin solubilisation of bovine 
caudate nucleus D2 receptors (not shown), benze- 
thonium does not improve the binding profile sug- 
gesting that proteinase inhibition is a less likely 
explanation. 
The affinities of substances for binding to the 
LP~-solubilised preparation (table 1) show a good 
correlation with binding affinities at membrane- 
bound receptors supporting the idea that DZ recep- 
tors are being studied. Also we have verified by 
electron microscopy, ultrafiltration and sucrose 
density gradient centrifugation that the receptors 
are truly solubilised rather than present on small 
membrane fragments. 
The use of LPC in the presence of proteinase in- 
hibitors as above, therefore, provides a useful 
method for solubilisation of brain D2 receptors. 
LPC, therefore, offers an alternative to digitonin 
which has been widely used for this purpose and 
overcomes some of the problems inherent in the 
use of digitonin such as its solubility and the varia- 
bility of composition of commercial preparations. 
Here it seems that as the starting membrane 
preparation contains a mixture of serotonergic and 
dopaminergic sites, whereas the solubilised 
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preparation contains only dopaminergic sites, LPC 
is specifically extracting dopaminergic sites or 
alternatively the serotonergic sites are also ex- 
tracted but not detected in the assay conditions. 
Although the LPC-solubilised preparation offers 
an attractive preparation for work on solubilised 
DZ receptors, specific [3H]spiperone binding still 
comprises only about half the total [3H]spiperone 
binding. However, we have managed to increase 
the proportion of specific binding considerably by 
carrying out the binding assays at 25°C rather than 
4°C (unpublished). 
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